Live
FierceBiotechVertex races to FDA after phase 3 kidney disease data impress analystsFierceBiotechBioNTech's CEO, CMO prep departure to set up next-gen mRNA spinoutFierceBiotechBreakout Ventures launches $114M AI-focused fundEndpoints NewsBreakout Ventures closes $114M fund, plans 20 investmentsEndpoints NewsBioNTech co-founders to exit company and start a new oneBioWorldAppointments and advancements for March 10, 2026BioWorldIn the clinic for March 10, 2026BioWorldOther news to note for March 10, 2026BioWorldRegulatory actions for March 10, 2026IlluminaHow Singapore is solidifying its role at the forefront of global genomics - Illumina10x Genomics BlogCathie Wood’s ARK trims 10X Genomics stock, adds DraftKings By Investing.com - Investing.com South AfricaFierceBiotechAI could help spot heart disease in routine breast mammogram screenings
FierceBiotech Mar 10, 2026

Vertex races to FDA after phase 3 kidney disease data impress analysts

Vertex races to FDA after phase 3 kidney disease data impress analysts

Original
Body unavailable. Use the original source.

Directory

59 All